CClinicalTrials.gg
TerminatedNCT05820997Updated Dec 16, 2025Results posted

Paravertebral Block vs no Block in Open Pancreaticoduodenectomy

A Phase 4 interventional study of Ropivacaine in Pancreaticoduodenectomy, sponsored by Mayo Clinic. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Supportive care

Why this study was terminated
Low accrual
Phase
Phase 4
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare intra and postoperative pain control between Paravertebral block vs no block in open pancreaticoduodenectomy. Length of stay, and complications will also be recorded. For this study the investigator plans to randomize to obtain objective data for clinical decisions and improve patient outcomes. Following surgery patients in both groups, data will be collected from the first 48 hours after surgery and at discharge.

02

Conditions studied

  • Pancreaticoduodenectomy
03

In context

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients willing and have signed consent.
  • Nonpregnant adults undergoing open pancreaticoduodenectomy via standard upper midline incision without contraindications to para vertebral block (PVB)

Exclusion criteria

Exclusion Criteria:

  • Not able or unwilling to sign consent.
  • Currently pregnant or lactating.
  • Patients with chronic pain, requiring daily opiate use at time of surgery.
  • Patients intolerant of opiates, NSAIDS, acetaminophen or local anesthetics.
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Active comparator
    Paravertebral Block Pre Procedure

    Subject will receive a preoperative paravertebral block only

    Drug: Ropivacaine

  • No intervention
    No Paravertebral Block

    Subject will receive no paravertebral block.

Interventions

  • DrugRopivacaine

    Paravertebral at the T7-10 levels bilaterally with 5 cc of 0.5% ropivacaine at each level

06

What researchers measure

Primary outcomes

  1. Mean Post-operative Pain Score

    The VAS is a 11-item questionnaire assessing pain. Using a scale of 0 = no pain to 10 = worst pain. Total scores range from 0 - 110, lower scores indicating lower pain and higher scores indicating greater pain. The average score across the 11 questions was calculated for each subject using the minimum and maximum values reported for each subject across the 11 questions.

    Time frame: First 48 hours after surgery

Secondary outcomes

  1. Hospital Length of Stay

    Total number of days subjects were admitted to the hospital following surgery

    Time frame: Approximately 4-6 days post surgery

  2. Number of Subjects With a Bowel Obstruction

    Number of subjects to experience a bowl obstruction following surgery

    Time frame: Approximately 2-4 days

07

Results

Posted Dec 16, 2025
Limitations and caveats
The study was terminated due to low accrual.

Participant flow

Participant flow — Overall Study
MilestoneParavertebral Block Pre ProcedureNo Paravertebral Block
Started11
Completed11
Not completed00

Outcome measures

PrimaryMean Post-operative Pain Score

The VAS is a 11-item questionnaire assessing pain. Using a scale of 0 = no pain to 10 = worst pain. Total scores range from 0 - 110, lower scores indicating lower pain and higher scores indicating greater pain. The average score across the 11 questions was calculated for each subject using the minimum and maximum values reported for each subject across the 11 questions.

Time frame:
First 48 hours after surgery
Reported as:
Mean · score on a scale
Mean Post-operative Pain Score
score on a scaleParavertebral Block Pre ProcedureNo Paravertebral Block
Mean Post-operative Pain Score5 (2 to 8)4 (0 to 8)
SecondaryHospital Length of Stay

Total number of days subjects were admitted to the hospital following surgery

Time frame:
Approximately 4-6 days post surgery
Reported as:
Number · days
Hospital Length of Stay
daysParavertebral Block Pre ProcedureNo Paravertebral Block
Hospital Length of Stay56
SecondaryNumber of Subjects With a Bowel Obstruction

Number of subjects to experience a bowl obstruction following surgery

Time frame:
Approximately 2-4 days
Reported as:
Count of participants · Participants
Number of Subjects With a Bowel Obstruction
ParticipantsParavertebral Block Pre ProcedureNo Paravertebral Block
Number of Subjects With a Bowel Obstruction00

Adverse events

Collected over Adverse events were collected from the time of surgery until time of discharge, approximately 6 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paravertebral Block Pre Procedure0/1 (0%)0/1 (0%)0/1 (0%)
No Paravertebral Block0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventParavertebral Block Pre ProcedureNo Paravertebral Block
lleusGastrointestinal disorders0/11/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Paravertebral Block Pre ProcedureNo Paravertebral BlockTotal
<=18 years000
Between 18 and 65 years101
>=65 years011
Sex: Female, Male
Sex: Female, Male(Participants)Paravertebral Block Pre ProcedureNo Paravertebral BlockTotal
Female000
Male112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Paravertebral Block Pre ProcedureNo Paravertebral BlockTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White112
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Paravertebral Block Pre ProcedureNo Paravertebral BlockTotal
United States112
08

Study locations

1 site
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 17, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05820997
Lead sponsor
Mayo Clinic
Responsible party
John A. Stauffer (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Apr 20, 2023
Start date
Apr 24, 2023
Primary completion
Dec 4, 2024
Completion
Dec 4, 2024
Results posted
Dec 16, 2025
Last update
Dec 16, 2025

Study contacts

John Stauffer, M.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion